APAC / ASEAN
-
Business Case Creation for a US-Based Novel Blood Glucose Monitoring Company
- November 18, 2015
- Posted by: Team EMeRG
- Category: APAC / ASEAN, BY BUSINESS CHALLENGES, BY MEDICAL TECHNOLOGIES, Diabetes Management, Market Entry Assessment, NPI Research, Pricing Research
No Comments
“CGM with infusion pump is very expensive for patients to buy. In India, hardly a few patients have CGM - let alone infusion pumps. Now with newer technology I hope cost comes down and more patients have access to continuous monitoring. In Metropolitan cities around 5 % of the diabetic population would buy SMBG monitors. -
New Product Introduction – Integrated Vital Signs Monitoring Solution
- November 9, 2015
- Posted by: Team EMeRG
- Category: APAC / ASEAN, BY MEDICAL TECHNOLOGIES, Competitive Intelligence, Ethnographic Research, Market Entry Assessment, NPI Research, Patient Monitoring, Pricing Research, Value Prop Assessment
Overview: Vital Signs Monitoring Market in India Valued at over $3.5Bn, the global vital signs market is demonstrating significant growth in emerging markets especially across secondary care. With the need for early detection, and quick diagnosis prior to referrals, the need for vital signs monitoring is on the rise in primary care settings. The market -
Assessing reimbursement and pricing strategies for medical consumables and insulin delivery systems
- September 9, 2014
- Posted by: Team EMeRG
- Category: APAC / ASEAN, BY MEDICAL TECHNOLOGIES, Diabetes Management, GTM Strategy, Medical consumables, Pricing Research
Overview: Market for Insulin Delivery in India With >69Mn cases, diabetes represents significant disease burden in India. In Urban India, approximately 12% of adults live with diabetes, compared to only 7% in the United States and the United Kingdom. Indian insulin market is valued at over $230Mn with Novo Nordisk being the market leader. While rapid
- 1
- 2
